To our knowledge, ACHIEVE was the first prospective study specifically designed to assess the activity and safety of high-dose aumolertinib in patients with untreated EGFR-variant metastatic NSCLC and brain metastases. This evidence concerns the gene EGFR and non-small cell lung carcinoma.